# Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults

> **NCT05938946** · PHASE1 · COMPLETED · sponsor: **Pharmosa Biopharm Inc.** · enrollment: 64 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** L608 Inhalation Solution
- **DRUG:** Placebo solution

## Key facts

- **NCT ID:** NCT05938946
- **Lead sponsor:** Pharmosa Biopharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-30
- **Primary completion:** 2024-09-02
- **Final completion:** 2024-09-02
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938946, "Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05938946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*